for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Zhejiang Hisun Pharmaceutical Co., Ltd.

600267.SS

Latest Trade

13.70CNY

Change

-0.17(-1.23%)

Volume

7,354,944

Today's Range

13.47

 - 

13.92

52 Week Range

12.48

 - 

21.97

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Zhejiang Hisun Pharmaceutical's 2020 Net Profit Up 348.3% Y/Y

March 22 (Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS>::SAYS 2020 NET PROFIT UP 348.3% Y/Y AT 417.2 MILLION YUAN ($64.12 million).

Zhejiang Hisun Pharma Gets Regulatory Approval For Asset Acquisition, Share Trade To Resume

Dec 25 (Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS>::SAYS IT GETS SECURITIES REGULATOR'S APPROVAL FOR ASSET ACQUISITION, TRADING IN SHARES TO RESUME ON DEC 28.

Zhejiang Hisun Pharma's Trading In Shares To Halt Pending Regulatory Review Of Asset Acquisition

Dec 24 (Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS>::SAYS TRADING IN SHARES TO HALT FROM DEC 25 PENDING REGULATORY REVIEW OF ITS ASSET ACQUISITION PLAN.

Zhejiang Hisun Pharmaceutical's 9-Mth Net Profit Down 72.7% Y/Y

Oct 28 (Reuters) - Zhejiang Hisun Pharmaceutical <600267.SS>::SAYS 9-MONTH NET PROFIT DOWN 72.7% Y/Y.

Zhejiang Hisun Pharma Agrees To Buy 49% Stake In JV Via Cash, Share And Bond Issue

July 20 (Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS>::SAYS IT PLANS TO BUY 49% STAKE IN ITS PHARMA JV FROM HPPC FOR 4.3-4.5 BILLION YUAN ($615.32-643.94 million) VIA CASH, SHARE AND CONVERTIBLE BOND ISSUES.SAYS IT AIMS TO RAISE UP TO 1.5 BILLION YUAN THROUGH SHARE AND CONVERTIBLE BOND ISSUES TO FUND THE ACQUISITION.SAYS TRADING IN SHARES TO RESUME ON JULY 21.

Corrected-Zhejiang Hisun Pharma gets approval for clinical trial to test flu drug Favipiravir for pneumonia caused by new coronavirus

Corrects headline and bullets to show company gets approval for clinical trial to test Favipiravir for pneumonia caused by novel coronavirus:RECEIVES APPROVAL TO MANUFACTURE FAVIPIRAVIR FOR NEW AND RECURRING INFLUENZA IN ADULTS.SAYS IT RECEIVES APPROVAL TO START CLINICAL TRIALS FOR USE OF FAVIPIRAVIR TO TREAT PNEUMONIA CAUSED BY NEW CORONAVIRUS.

Zhejiang Hisun Pharmaceutical says receives approval to start selling coronavirus treatment - company filing

Feb 16 (Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS>::RECEIVES APPROVAL TO START SELLING FAVIPIRAVIR AS POTENTIAL TREATMENT FOR NOVEL CORONAVIRUS - COMPANY FILING.SAYS MUST STILL CONTINUE CLINICAL TRIALS AFTER FAVIPIRAVIR HITS MARKET AS POTENTIAL CORONAVIRUS TREATMENT - COMPANY FILING.

Zhejiang Hisun Pharmaceutical's 9-Month Net Profit Up Rises To 1.3 Bln Yuan

Oct 30 (Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS>::SAYS 9-MONTH NET PROFIT UP 17,542.0% Y/Y AT 1.3 BILLION YUAN ($184.21 million).

PAG Highlander (Hk) To Invest 3.8 Bln Yuan In Zhejiang Hisun Pharma's Unit For 58% Stake

Sept 4 (Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS>::SAYS PAG HIGHLANDER (HK) LTD AGREES TO INVEST 3.8 BILLION YUAN ($535.75 million) IN ITS BIO-PHARMA UNIT FOR 58% STAKE.

Zhejiang Hisun Pharmaceutical To Boost Unit's Capital, Sell Shares in Unit, Unit To Sell Property

June 21 (Reuters) - Zhejiang Hisun Pharmaceutical Co Ltd <600267.SS>::SAYS IT PLANS TO BOOST BIOMEDICAL UNIT'S CAPITAL BY AT LEAST 1.0 BILLION YUAN BY BRINGING IN INVESTORS.SAYS IT PLANS TO SELL SHARES IN BIOMEDICAL UNIT FOR AT LEAST 2.8 BILLION YUAN ($407.52 million).SAYS UNIT PLANS TO SELL PROPERTY FOR AT LEAST 290 MILLION YUAN.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up